TCGA-DK-AA77-01A-11R-A39I-07
—
Clinical attributes
From the source cohort, normalized into canonical keys plus the project's native columns.
- cancer_type
- —
- cancer_type_detailed
- —
- subtype
- —
- overall_survival_months
- 20.3022339
- os_event
- false
- sex
- Male
GSVA pathway preview (50 Hallmark scores)
Top 10 most elevated and top 10 most suppressed Hallmark pathways for this sample.
Top 10 elevated
- UNFOLDED_PROTEIN_RESPONSE+0.490
- INTERFERON_ALPHA_RESPONSE+0.440
- MTORC1_SIGNALING+0.440
- MYC_TARGETS_V1+0.440
- PROTEIN_SECRETION+0.420
- ANDROGEN_RESPONSE+0.390
- CHOLESTEROL_HOMEOSTASIS+0.340
- INTERFERON_GAMMA_RESPONSE+0.330
- OXIDATIVE_PHOSPHORYLATION+0.320
- ADIPOGENESIS+0.310
Top 10 suppressed
- EPITHELIAL_MESENCHYMAL_TRANSITION-0.520
- PANCREAS_BETA_CELLS-0.490
- ANGIOGENESIS-0.430
- COAGULATION-0.320
- HEDGEHOG_SIGNALING-0.320
- WNT_BETA_CATENIN_SIGNALING-0.300
- MYOGENESIS-0.290
- APICAL_JUNCTION-0.240
- APICAL_SURFACE-0.240
- KRAS_SIGNALING_DN-0.200
Patient twins — nearest pathway neighbors
10 samples closest to this one in 50-dim pathway space, drawn from the Pathway Atlas. Cosine similarity = 1 means identical pathway state.
7 twins match this tumor's tissue · 3 come from a different tissue of origin
| # | Sample | Cancer type | Subtype | cos similarity |
|---|---|---|---|---|
| 1 | R190 | — | — | 0.873 |
| 2 | TCGA-A2-A0YT-01A-11R-A109-07 | — | B | 0.843 |
| 3 | BS_W80TJC27 | Supratentorial Ependymoma | — | 0.842 |
| 4 | SRR650153 | — | — | 0.818 |
| 5 | BS_W80TJC27 | EPN | Supratentorial EPN | 0.816 |
| 6 | TCGA-HQ-A5ND-01A-11R-A26T-07 | — | — | 0.813 |
| 7 | 81b828aa-cb06-4790-ba3e-efaa39f4eeef | — | — | 0.813 |
| 8 | BS_CZ3ER8DY | Supratentorial Ependymoma | — | 0.808 |
| 9 | TCGA-CQ-6220-01A-11R-1915-07 | — | — | 0.802 |
| 10 | R128 | — | — | 0.801 |
Per-pathway drug coverage
For each elevated pathway in this tumor, the best-reversing drug across the catalog. Uncovered pathways = unmet need at pathway level for this one patient.
0 of 30 elevated pathways have at least one drug that meaningfully reverses them.
| Pathway (elevated) | tumor score | Best drug | reversal magnitude |
|---|---|---|---|
| UNFOLDED_PROTEIN_RESPONSE | 0.490 | Idelalisib | — uncovered |
| INTERFERON_ALPHA_RESPONSE | 0.440 | Inavolisib | — uncovered |
| MTORC1_SIGNALING | 0.440 | Inavolisib | — uncovered |
| MYC_TARGETS_V1 | 0.440 | Inavolisib | — uncovered |
| PROTEIN_SECRETION | 0.420 | Remibrutinib | — uncovered |
| ANDROGEN_RESPONSE | 0.390 | Inavolisib | — uncovered |
| CHOLESTEROL_HOMEOSTASIS | 0.340 | Remibrutinib | — uncovered |
| INTERFERON_GAMMA_RESPONSE | 0.330 | Idelalisib | — uncovered |
| OXIDATIVE_PHOSPHORYLATION | 0.320 | Remibrutinib | — uncovered |
| ADIPOGENESIS | 0.310 | Inavolisib | — uncovered |
| PI3K_AKT_MTOR_SIGNALING | 0.300 | Inavolisib | — uncovered |
| E2F_TARGETS | 0.280 | Inavolisib | — uncovered |
| G2M_CHECKPOINT | 0.280 | Inavolisib | — uncovered |
| GLYCOLYSIS | 0.260 | Inavolisib | — uncovered |
| PEROXISOME | 0.240 | Idelalisib | — uncovered |
| DNA_REPAIR | 0.220 | Idelalisib | — uncovered |
| ESTROGEN_RESPONSE_EARLY | 0.210 | Inavolisib | — uncovered |
| HYPOXIA | 0.200 | Idelalisib | — uncovered |
| MYC_TARGETS_V2 | 0.200 | Idelalisib | — uncovered |
| FATTY_ACID_METABOLISM | 0.150 | Inavolisib | — uncovered |